RAD to present at NWR Virtual Healthcare Conference
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
19 MARCH 2024
Radiopharm to present at NWR Virtual Healthcare Conference
Sydney, Australia – 19 March 2024 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the
“Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology
radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that it will
present at the NWR Virtual Healthcare Conference.
Chief Operating Officer Vittorio Puppo will present at 9:00am AEDT on Thursday 21 March 2024.
Shareholders, investors and interested parties are encouraged to register to attend the presentation
at the following link: https://us02web.zoom.us/webinar/register/WN_z-nNb9jZQum5W6o_HIFn6g
A recording will be available at the above link shortly after the conclusion of the live session, and the
replay will also be available via the Company’s website and social media channels.
Questions can be submitted on the day or sent in advance to matt@nwrcommunications.com.au
For more information please visit: https://nwrcommunications.com/healthconf
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage company developing a world-class platform of innovative
radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet
medical need. Radiopharm has been listed on the ASX (RAD) since November 2021. The company
has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small
molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of
development from some of the world’s leading universities and institutes. The pipeline has been
built based on the potential to be first-to-market or best-in-class. The clinical program includes one
Phase II and two Phase I trials in a variety of solid tumour cancers including lung, pancreas and brain.
Learn more at Radiopharmtheranostics.com.
Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman
Paul Hopper.
For more information:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
ASX ANNOUNCEMENT
19 MARCH 2024
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Linked In – https://www.linkedin.com/company/radiopharmtheranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
Share your feedback
Discover